Dupilumab treatment in children aged 6–11 years with severe atopic dermatitis is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels - 08/04/23
, A. Wollenberg 2, E.C. Siegfried 3, A.B. Rossi 4, ⁎ , Z. Chen 5, N.A. Levit 5, A. Rodriguez Marco 6Résumé |
Introduction (contexte de la recherche) |
Atopic dermatitis (AD) is a chronic systemic inflammatory condition predominantly driven by dysregulated type 2 immunity. AD and other type 2 inflammatory comorbidities associated with elevated serum IgE and Thymus and activation-regulated chemokine (TARC) are particularly common in children aged 6–11 years. Dupilumab studies have previously demonstrated the suppression of type 2 biomarkers including IgE across multiple diseases in adults.
Objectif |
To present the effect of dupilumab on serum IgE and TARC levels in children aged 6–11 years with severe AD.
Méthodes |
In the LIBERTY AD PEDS study (NCT03345914), children were randomized 1:1:1 to dupilumab 300mg every 4 weeks (q4w), 100mg/200mg every 2 weeks, or placebo, with concomitant medium-potency topical corticosteroids (TCS). Mean absolute serum IgE and TARC levels (standard deviation [SD]) were evaluated at Baseline/week 16 and Baseline/week 4/week 16, respectively. Only data for the EMA-approved 300mg q4w dupilumab dosing regimens (n=122) and placebo treated (n=123) groups are shown.
Résultats |
IgE concentrations (SD) were similar across both groups and markedly elevated at baseline (placebo: 9561.7 kU/L [12,955.4]; dupilumab: 9,755.5 kU/L [13,635.1]). In the placebo group, IgE concentrations remained elevated at week 16 (8,258.7 kU/L [10,541.5]). Dupilumab treatment substantially reduced IgE concentrations compared to baseline (3,458.0 kU/L [5,113.9]) at week 16. TARC concentrations (SD) were similar across both groups at baseline (placebo: 4,364.1pg/mL [7,656.2]; dupilumab: 3,239.1pg/mL [6,276.1]). Dupilumab treated patients demonstrated a large and sustained reduction in TARC concentration compared to placebo at week 4 (placebo: 2,743.6pg/mL [3,393.1]; dupilumab: 668.9pg/mL [613.0]) and week 16 (placebo: 2,591.6pg/mL [3,637.7]; dupilumab: 508.4pg/mL [566.7]). Dupilumab was generally well tolerated with a favourable safety profile.
Conclusions |
Dupilumab treatment reduces serum TARC and IgE levels in paediatric patients aged 6–11 years old with severe AD over 16 weeks, reflecting robust abrogation of systemic type 2 inflammation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 63 - N° 3
Article 103436- avril 2023 Retour au numéro
Article précédent
- Place des pricks tests dans la prise en charge des allergies aux implants métalliques
- A. Pequignot, M. Cola, F. Berard, F. Hacard, J.F. Nicolas, A. Nosbaum
- Laboratory safety from a 16-week, phase 3 study of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
- A.S. Paller, A. Wollenberg, E.C. Siegfried, M.E. Gonzalez, B.L. Lockshin, A.B. Rossi, F.A. Khokhar, Z. Chen, T. Gonzalez, R. Prescilla
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?